EU External Trade - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale

Extra-EU sourcing of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale is highly concentrated. 🇺🇸 United States captures 51.6% of imports (€21.6B), followed by 🇰🇷 South Korea (24.6%). With an HHI of 3453, this Concentrated market exposes the EU to supply dependency risks.

European exports of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale are concentrated on a few markets. 🇺🇸 United States accounts for 86.1% (€29.6B), ahead of 🇨🇭 Switzerland (7.4%). The top three destinations are 🇺🇸 United States, 🇨🇭 Switzerland, 🇬🇧 United Kingdom.

Within the EU, the leading importers of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, mixed, not put up in measured doses or in forms or packings for retail sale are 🇩🇪 Germany, 🇧🇪 Belgium, 🇳🇱 Netherlands. 🇩🇪 Germany accounts for 23.7% of EU imports.

In 2025, trade flows diverged: imports were surging (40.0%) while exports were falling sharply (-46.0%), signalling a structural market shift.